CLOs on the Move

ValGenesis

www.valgenesis.com

 
As a pioneer in the development of automated validation software solutions, ValGenesis leads the way with a unique paperless validation process that tracks the validation status of any GxP system in real time. With years of development and refinement in place, ValGenesis is the first to offer users real-time paperless validation via electronic execution thereby minimizing ineffectiveness and maximizing efficiency. ValGenesis automates and manages the validation life cycle and provides real time validation status of any system corporate wide.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.valgenesis.com
  • 395 Oyster Point Boulevard Suite 228
    South San Francisco, CA USA 94080
  • Phone: 510.445.0505

Executives

Name Title Contact Details
Steven Franckhauser
Chief Legal Counsel Profile

Similar Companies

Aker BioMarine

Aker BioMarine is a Norwegian fishing and biotech company providing krill products through a fully documented and secured catch and process chain.

New Jersey Precision Technology

New Jersey Precision Technology is a Mountainside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abbott Diabetes Care

Abbott Diabetes Care is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entrinsic Bioscience

entrinsic bioscience is a recognized leader in the development, manufacturing and commercialization of disruptive, science-derived amino-acid technologies that are clinically-proven to deliver better health outcomes in a broad range of therapeutic areas including gut health, hydration, skin and respiratory health.

Regado Biosciences

Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.